Hangzhou Duanben Pharmaceutical Technology

Hangzhou Duanben Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Hangzhou, China, dedicated to the development of innovative targeted protein degradation (TPD) therapies. The company utilizes a proprietary molecular glue discovery platform to identify small molecules that facilitate the degradation of disease-relevant proteins previously considered undruggable. Its lead program, DB-1301, is a potent GSPT1 degrader currently undergoing clinical evaluation for the treatment of advanced solid tumors and hematological malignancies. Duanben's research and development efforts are supported by a team of experts in structural biology, medicinal chemistry, and computational drug design. The company has successfully secured significant venture capital funding from prominent investors to advance its diverse pipeline of oncology-focused candidates. By focusing on molecular glues, Duanben aims to provide transformative treatment options for patients with limited therapeutic alternatives.